Shareholders who purchased shares of LFMD during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/lifemd-inc-loss-submission-form/?id=170976&from=4Â CLASS PERIOD: May 7, 2025 to August 5, 2025 ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements ...

NEW YORK, Oct. 03, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of LifeMD, Inc. (NASDAQ: LFMD) between May 7, 2025 and August 5, 2025, both dates inclusive (the “Class Period”), of the important October 27, 2025 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased LifeMD securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or c ...

Group 1 - A class action has been filed against LifeMD, Inc. (NASDAQ: LFMD) on behalf of investors who acquired its securities between May 7, 2025, and August 5, 2025 [1][2] - The allegations include that LifeMD misled investors about its competitive position and failed to properly account for rising customer acquisition costs, particularly in its RexMD segment and for obesity treatment drugs [2] - Following the announcement of its second quarter 2025 results and a revision of its full-year guidance, LifeMD's stock price dropped by $5.31, or 44.8%, closing at $6.53 on August 6, 2025 [3] Group 2 - Shareholders interested in serving as lead plaintiffs must file their papers with the court by October 27, 2025, and can choose to remain absent class members if they do not wish to participate [4] - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses for representation [5]

SAN FRANCISCO, Oct. 01, 2025 (GLOBE NEWSWIRE) -- A federal securities fraud class action lawsuit has been filed in the Eastern District of New York against LifeMD, Inc. (NASDAQ: LFMD) and its executives. The lawsuit alleges that the telehealth company presented a misleadingly optimistic image of its financial health and growth prospects, which ultimately led to a dramatic stock price decline in August. The suit, Johnston v. LifeMD, Inc., is seeking to recover damages for investors that purchased LifeMD secu ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In LifeMD (LFMD) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in LifeMD between May 7, 2025 and August 5, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- What’s Happening: Bragar ...

NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of LifeMD, Inc. (NASDAQ: LFMD). Shareholders who purchased shares of LFMD during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/lifemd-inc-loss-submission-form/?id=169640&from=3 CLASS PERIOD: May 7, 2025 to Augus ...

SAN FRANCISCO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- A new federal securities fraud class action lawsuit has been filed against LifeMD, Inc. (NASDAQ: LFMD) and its executives. The suit alleges the telehealth company presented a misleadingly optimistic picture of its financial health and growth, ultimately resulting in a dramatic stock price decline in August. The action was filed in the Eastern District of New York. The lawsuit, Johnston v. LifeMD, Inc., focuses on the period between May 7, 2025, and August 5, ...

Core Viewpoint - A federal securities fraud class action lawsuit has been filed against LifeMD, alleging misleading representations regarding its financial health and growth prospects, following a significant stock price decline after its earnings report in August 2025 [1][7]. Summary by Relevant Sections Lawsuit Details - The lawsuit, titled Johnston v. LifeMD, Inc., covers the period from May 7 to August 5, 2025, claiming that LifeMD made false statements, particularly during its first-quarter results announcement on May 6, 2025, when it raised its full-year revenue and adjusted EBITDA guidance [5][6]. - The complaint asserts that LifeMD's optimistic outlook regarding its competitive position in virtual obesity care and performance from its RexMD brand was misleading, as it did not disclose significant operational challenges [5][6]. Financial Performance and Stock Impact - LifeMD reportedly faced rising customer acquisition costs in its RexMD segment and a higher-than-expected refund rate in its weight management business, which were not disclosed to investors [6]. - The situation escalated on August 5, 2025, when LifeMD announced second-quarter results that missed revenue and earnings per share estimates, leading to a drastic reduction in its full-year guidance. Following this announcement, the company's stock price dropped by over 44% [7]. Investor Actions - The lawsuit provides an opportunity for investors who incurred substantial losses during the specified period to seek recovery [8]. - Hagens Berman, the law firm investigating the claims, is looking into whether LifeMD was aware of but failed to disclose key operational issues [10].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of LifeMD, Inc. regarding a class action lawsuit due to alleged misleading statements and failure to disclose critical information during a specified class period [1][3]. Group 1: Allegations - The complaint alleges that during the class period from May 7, 2025, to August 5, 2025, LifeMD's management materially overstated the company's competitive position [3]. - It is claimed that the defendants were reckless in raising LifeMD's 2025 guidance without properly accounting for rising customer acquisition costs in the RexMD segment and related to obesity treatment drugs like Wegovy and Zepbound [3]. - As a result, the statements made by the defendants regarding LifeMD's business, operations, and prospects were materially false and misleading, lacking a reasonable basis at all relevant times [3]. Group 2: Class Action Details - The deadline for shareholders to register for the class action is October 25, 2025, and they are encouraged to register promptly [4]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive status updates throughout the lifecycle of the case [4]. - Participation in the case does not incur any cost or obligation for the shareholders [4]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered due to deceit, fraud, and illegal business practices [5]. - The firm aims to ensure that companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements that led to artificial inflation of stock prices [5].

Core Viewpoint - A class action lawsuit has been filed against LifeMD, Inc. for allegedly misleading investors about its business prospects during the period from May 7, 2025, to August 5, 2025 [1][2]. Group 1: Allegations and Misconduct - The lawsuit claims that LifeMD's management materially overstated the company's competitive position and recklessly raised its 2025 guidance without properly accounting for rising customer acquisition costs in its RexMD segment and related to obesity treatment drugs [2]. - The defendants' statements regarding LifeMD's business operations and prospects were allegedly materially false and misleading, lacking a reasonable basis throughout the relevant period [2]. Group 2: Financial Impact - Following the announcement of its second quarter 2025 results on August 5, 2025, which indicated temporary challenges in the RexMD business, LifeMD revised its full-year 2025 revenue and adjusted EBITDA guidance, leading to a significant stock price drop of $5.31 per share, or 44.8%, closing at $6.53 on August 6, 2025 [3]. Group 3: Legal Proceedings - Shareholders interested in participating as lead plaintiffs in the class action must file their papers with the court by October 27, 2025 [4]. - The lead plaintiff will represent other class members in directing the litigation, although participation is not required to be eligible for recovery [4]. Group 4: Company Background - Robbins LLP, the law firm handling the case, has been dedicated to helping shareholders recover losses and improve corporate governance since 2002 [5].